Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albert Jarvi

Family Medicine Salt Lake City, UT Medical Doctor

NPI 1265966733 CMS profile 7228138

24 S 1100 E Ste 310, Salt Lake City, UT 84102

Open in the dashboard

General payments

$3,423

192 records reported · program years 2019–2025

Research payments

$2,843

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,627,980 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Albert Jarvi of Salt Lake City, UT is reported in the CMS Open Payments database as having received $3,423 across 192 general payments and $2,843 in research payments paid to them. Separately, studies naming them as principal investigator received $1,627,980 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $656 32
2024 General $598 33
2024 Research $2,313 3
2023 General $773 43
2023 Research $530 1
2022 General $731 45
2021 General $632 37
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Jarvi
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Albert Jarvi were reported at $656. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Albert Jarvi Family Medicine median Middle half National median
2019 $34 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $632 $137 $35–$551 $132
2022 $731 $137 $37–$512 $149
2023 $773 $149 $42–$545 $160
2024 $598 $156 $44–$560 $164
2025 $656 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $328 15 payments
  2. AstraZeneca Pharmaceuticals LP $323 21 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $264 12 payments
  4. ViiV Healthcare Company $255 12 payments
  5. Lilly USA, LLC $245 15 payments
  6. Novo Nordisk Inc $208 12 payments
  7. Merck Sharp & Dohme Corporation $204 12 payments
  8. GlaxoSmithKline, LLC. $190 13 payments
  9. Amgen Inc. $171 10 payments
  10. Exact Sciences Corporation $148 8 payments
  11. Other $1,087 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,423 192 payments
Products named General payments · program years 2019–2025
  1. SHINGRIX $176 12 payments
  2. Ozempic $175 10 payments
  3. RYBELSUS $169 10 payments
  4. MOUNJARO $160 10 payments
  5. Repatha $154 9 payments
  6. Otezla $151 9 payments
  7. Cologuard Collection Kit $148 8 payments
  8. APRETUDE $147 7 payments
  9. Kerendia $146 8 payments
  10. GARDASIL 9 $122 7 payments
  11. Other $3,152 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,472 2 payments
  2. Lexicon Pharmaceuticals, Inc. $371 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

4,365

Median for Family Practice: 1,826

Drug cost

$300,417

Median for Family Practice: $120,094

Branded share of claims

20.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 66 $70,502
Farxiga Dapagliflozin Propanediol Brand 36 $44,792
Xarelto Rivaroxaban Brand 32 $34,444
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $19,680
Januvia Sitagliptin Phosphate Brand 18 $15,704
Myrbetriq Mirabegron Brand 15 $14,681
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $13,512
Tradjenta Linagliptin Brand 17 $9,893
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $8,355
Spiriva Handihaler Tiotropium Bromide Brand 11 $7,706

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$30,556

Medicare's payments for the services billed

Medicare patients

137

Average age 74

Services billed

474

63 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 39%
Depression 24%
Diabetes 20%
Ischemic heart disease 20%
Chronic kidney disease 19%
Heart failure 13%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
  • ViiV Healthcare Company $100
$100 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $73
  • Lilly USA, LLC $9
$82 — —
MOUNJARO
  • Lilly USA, LLC $67
$67 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $30
$30 — —
AREXVY
  • GlaxoSmithKline, LLC. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record